0.5725
price down icon2.19%   -0.0155
 
loading
前日終値:
$0.588
開ける:
$0.571
24時間の取引高:
97,266
Relative Volume:
0.21
時価総額:
$24.28M
収益:
$1.38M
当期純損益:
$-179.05M
株価収益率:
-0.0805
EPS:
-7.11
ネットキャッシュフロー:
$-155.03M
1週間 パフォーマンス:
+10.51%
1か月 パフォーマンス:
+4.72%
6か月 パフォーマンス:
-71.39%
1年 パフォーマンス:
-85.25%
1日の値動き範囲:
Value
$0.565
$0.5801
1週間の範囲:
Value
$0.511
$0.6114
52週間の値動き範囲:
Value
$0.50
$4.17

Bioxcel Therapeutics Inc Stock (BTAI) Company Profile

Name
名前
Bioxcel Therapeutics Inc
Name
セクター
Healthcare (1195)
Name
電話
203-643-8060
Name
住所
555 LONG WHARF DRIVE, NEW HAVEN, CT
Name
職員
74
Name
Twitter
@bioxcel_tx
Name
次回の収益日
2024-11-12
Name
最新のSEC提出書
Name
BTAI's Discussions on Twitter

BTAI を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
BTAI 0.5701 24.28M 1.38M -179.05M -155.03M -7.11
VRTX 449.47 115.43B 10.63B -479.80M -1.35B 13.33
REGN 746.00 82.04B 13.85B 4.65B 3.32B 35.06
ARGX 594.28 35.30B 1.86B -40.29M -1.28B -4.16
ALNY 245.84 32.04B 2.09B -332.26M 16.06M -4.14
BNTX 108.00 24.89B 3.30B -501.07M 1.03B 11.54

Bioxcel Therapeutics Inc Stock (BTAI) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2023-08-15 ダウングレード Mizuho Buy → Neutral
2023-07-17 ダウングレード Guggenheim Buy → Neutral
2023-03-10 ダウングレード Jefferies Buy → Hold
2022-12-01 アップグレード Goldman Sell → Neutral
2022-07-07 開始されました Mizuho Buy
2022-04-06 繰り返されました BofA Securities Buy
2021-11-15 ダウングレード Goldman Neutral → Sell
2021-04-09 開始されました Berenberg Buy
2021-02-01 開始されました UBS Buy
2020-10-30 開始されました Goldman Buy
2020-09-02 開始されました Jefferies Buy
2020-08-17 繰り返されました H.C. Wainwright Buy
2020-07-08 繰り返されました H.C. Wainwright Buy
2020-06-04 開始されました Guggenheim Buy
2020-04-01 開始されました BofA/Merrill Buy
2020-02-26 繰り返されました H.C. Wainwright Buy
2020-01-08 繰り返されました H.C. Wainwright Buy
2019-11-12 開始されました SunTrust Buy
すべてを表示

Bioxcel Therapeutics Inc (BTAI) 最新ニュース

pulisher
Nov 18, 2024

BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Lags Revenue Estimates - MSN

Nov 18, 2024
pulisher
Nov 15, 2024

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 15, 2024
pulisher
Nov 15, 2024

BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings Call Highlights: Strategic Trials and Financial Adjustments - GuruFocus.com

Nov 15, 2024
pulisher
Nov 15, 2024

BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings Call Highlights: Strategic Trials and ... By GuruFocus - Investing.com Canada

Nov 15, 2024
pulisher
Nov 15, 2024

BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings Call Highlights: Strategic Trials and ... - Yahoo Finance

Nov 15, 2024
pulisher
Nov 15, 2024

BioXcel Therapeutics Inc. (BTAI) Quarterly 10-Q Report - Quartz

Nov 15, 2024
pulisher
Nov 14, 2024

BioXcel Therapeutics stock hits 52-week low at $0.5 By Investing.com - Investing.com Australia

Nov 14, 2024
pulisher
Nov 14, 2024

BioXcel Therapeutics Reports Q3 2024 Financial Results - TipRanks

Nov 14, 2024
pulisher
Nov 14, 2024

BioXcel Therapeutics stock hits 52-week low at $0.5 - Investing.com India

Nov 14, 2024
pulisher
Nov 14, 2024

Earnings call: BioXcel Therapeutics reports Q3 2024 financials - Investing.com

Nov 14, 2024
pulisher
Nov 14, 2024

BioXcel Therapeutics earnings beat by $0.19, revenue fell short of estimates - Investing.com Canada

Nov 14, 2024
pulisher
Nov 14, 2024

BioXcel Therapeutics Inc Reports Q3 2024 Earnings: Net Revenue a - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

BioXcel Therapeutics Reports Third Quarter 2024 Financial Results - GlobeNewswire

Nov 14, 2024
pulisher
Nov 14, 2024

Critical Survey: Emergent BioSolutions (NYSE:EBS) vs. BioXcel Therapeutics (NASDAQ:BTAI) - Defense World

Nov 14, 2024
pulisher
Nov 13, 2024

What To Expect From BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings - GuruFocus.com

Nov 13, 2024
pulisher
Nov 13, 2024

BioXcel Therapeutics (BTAI) Set to Announce Earnings on Thursday - Defense World

Nov 13, 2024
pulisher
Nov 12, 2024

BioXcel advances trials for acute agitation treatments - Investing.com India

Nov 12, 2024
pulisher
Nov 12, 2024

BioXcel advances trials for acute agitation treatments By Investing.com - Investing.com UK

Nov 12, 2024
pulisher
Nov 12, 2024

BioXcel Therapeutics Advances Pivotal Phase 3 Trials of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders, Schizophrenia, and Alzheimer's Dementia - The Manila Times

Nov 12, 2024
pulisher
Nov 12, 2024

BioXcel Therapeutics Advances Pivotal Phase 3 Trials of - GlobeNewswire

Nov 12, 2024
pulisher
Nov 12, 2024

BioXcel's Phase 3 Breakthrough: First Patient Enrolled in Critical Agitation Treatment Trial | BTAI Stock News - StockTitan

Nov 12, 2024
pulisher
Nov 08, 2024

BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024 - GlobeNewswire

Nov 08, 2024
pulisher
Nov 05, 2024

Will BioXcel Therapeutics, Inc. (BTAI) Report Negative Q3 Earnings? What You Should Know - MSN

Nov 05, 2024
pulisher
Oct 30, 2024

ROSEN, TRUSTED AND TOP RANKED INVESTOR COUNSEL, Encourages BioXcel Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionBTAI - Marketscreener.com

Oct 30, 2024
pulisher
Oct 29, 2024

BioXcel Therapeutics to Present at ThinkEquity Conference - The Manila Times

Oct 29, 2024
pulisher
Oct 28, 2024

Pre-market Movers: EVOK, HCTI, GLUE, MNPR... - RTTNews

Oct 28, 2024
pulisher
Oct 23, 2024

BioXcel Therapeutics (NASDAQ:BTAI) PT Lowered to $5.00 - Defense World

Oct 23, 2024
pulisher
Oct 19, 2024

BioXcel announces defense grant to UNC to fund study for treating acute stress disorder - MSN

Oct 19, 2024
pulisher
Oct 15, 2024

BioXcel Therapeutics partners with UNC for ASD trial By Investing.com - Investing.com Australia

Oct 15, 2024
pulisher
Oct 15, 2024

BioXcel Therapeutics partners with UNC for ASD trial - Investing.com India

Oct 15, 2024
pulisher
Oct 15, 2024

BioXcel Therapeutics Announces U.S. Department of Defense - GlobeNewswire

Oct 15, 2024
pulisher
Oct 15, 2024

BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 (Sublingual Dexmedetomidine) for Treating Acute Stress Disorder - StockTitan

Oct 15, 2024
pulisher
Oct 10, 2024

BioXcel Therapeutics reports executive transition - Investing.com India

Oct 10, 2024
pulisher
Oct 09, 2024

BioXcel Therapeutics reports executive transition By Investing.com - Investing.com Australia

Oct 09, 2024
pulisher
Oct 09, 2024

Investing in BioXcel Therapeutics Inc (BTAI) Is Getting More Attractive - Knox Daily

Oct 09, 2024
pulisher
Oct 04, 2024

BioXcel Therapeutics executive sells shares worth over $3,000 By Investing.com - Investing.com Australia

Oct 04, 2024
pulisher
Oct 04, 2024

BioXcel Therapeutics CSO sells shares worth $3,946 By Investing.com - Investing.com South Africa

Oct 04, 2024
pulisher
Oct 04, 2024

BioXcel Therapeutics executive sells shares worth $3,449 By Investing.com - Investing.com Australia

Oct 04, 2024
pulisher
Oct 04, 2024

BioXcel therapeutics officer Javier Rodriguez sells shares worth $3,774 By Investing.com - Investing.com South Africa

Oct 04, 2024
pulisher
Oct 03, 2024

Bioxcel therapeutics CFO sells shares worth $3,946 By Investing.com - Investing.com Canada

Oct 03, 2024
pulisher
Oct 03, 2024

Bioxcel therapeutics CFO sells shares worth $3,946 - Investing.com

Oct 03, 2024
pulisher
Oct 03, 2024

BioXcel Therapeutics executive sells shares worth over $3,000 - Investing.com

Oct 03, 2024
pulisher
Oct 03, 2024

BioXcel Therapeutics CSO sells shares worth $3,946 - Investing.com India

Oct 03, 2024
pulisher
Oct 03, 2024

BioXcel therapeutics officer Javier Rodriguez sells shares worth $3,774 - Investing.com

Oct 03, 2024
pulisher
Oct 03, 2024

BioXcel Therapeutics executive sells shares worth $3,449 - Investing.com

Oct 03, 2024

Bioxcel Therapeutics Inc (BTAI) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$18.98
price up icon 1.80%
$70.68
price down icon 0.42%
$38.38
price up icon 3.49%
$369.83
price up icon 1.48%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
大文字化:     |  ボリューム (24 時間):